Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
NodThera Limited currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being reviewed within a distinct art unit, reflecting a focused prosecution presence for the company. Because there is a distinct examiner involved, the company's immediate success in the Biotechnology & Pharmaceuticals field depends on the decisions of this individual.
KUCKLA, ANNA GRACE is the busiest examiner for the company, currently managing the 1 pending office action. As the examiner for the portfolio, her perspective will determine the outcome of the company's current patent efforts. There are no other examiners or art units to provide a baseline for comparison or to diversify the company's prosecution risk. Practitioners should focus their strategy on the specific feedback from KUCKLA, ANNA GRACE, as her case is the active matter in the portfolio. This environment allows for a targeted approach to the distinct art unit involved. A thorough response to the initial office action is necessary for advancement.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCKLA, ANNA GRACE | 1 | 53.8% | +51.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18906310 | PYRIDAZINE DERIVATIVES AND RELATED USES | KUCKLA, ANNA GRACE | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18906310 | PYRIDAZINE DERIVATIVES AND RELATED USES | KUCKLA, ANNA GRACE | 1626 | §102 | Non-Final OA | — | Pending | Oct 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNodThera Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Anna Grace Kuckla has the most, with 1 of NodThera Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
